|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The study confirmed that F-FDG PET/CT is useful in the preoperative evaluation of patients with pulmonary neuroendocrine tumours.
|
30640182 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
A pulmonary nodule without higher-than-background FDG avidity was later biopsied as a low-grade neuroendocrine tumor.
|
31306189 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous surgical intervention (including debulking surgery with R1 resection), higher cumulative dose of PRRT, and low FDG uptake of the tumour are associated with prolonged OS and PFS in patients with metastatic or advanced mediastinal NETs and were independent favourable prognostic markers.
|
31343606 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor.
|
30829861 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors.
|
31350186 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to compare, in a series of well-differentiated neuroendocrine tumors (NET), the 18F-FDG uptake and expression of the proliferation markers Ki-67, GLUT1, CA9, and pVHL.
|
28803235 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
|
28735662 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
18F-FDG PET/CT in Primary Hepatic Neuroendocrine Tumors.
|
29293142 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Although a higher proportion of <sup>18</sup>F-FDG PET-positive examinations were observed in patients with higher tumor grade (<i>p</i> = .01), 53.8% of patients with grade 1 neuroendocrine tumors (NETs) had positive <sup>18</sup>F-FDG PET, and 37.5% of patients with grade 2 NETs had negative <sup>18</sup>F-FDG PET.
|
29118267 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Adrenocorticotropic Hormone-Secreting Neuroendocrine Tumor of the Rectum Demonstrated on 68Ga-DOTATATE and 18F-FDG PET Imaging.
|
28759524 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
More recently, PET/CT imaging with <sup>18</sup>F-FDG, <sup>18</sup>F-fluorodihydroxyphenylalanine (FDOPA), and <sup>68</sup>Ga somatostatin-receptor ligands in NETs has been expanding.
|
28209907 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
|
27906872 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>18</sup>F-FDG PET/CT had no clinical impact on G1 NETs and a moderate impact on G2 NETs.
|
27516446 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
However, recent data showed that FDG imaging has prognostic value in patients with well-differentiated NET: high uptake was associated with an increased risk of early progression while low uptake suggested an indolent tumor.
|
28435455 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Aim:</i> The aim of this work was to develop a grading scheme that describes the joint results of both the FDG and somatostatin receptor imaging PET scans in staging subjects with neuroendocrine tumours in a single combined parameter.
|
28435454 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
|
28323985 |
2017 |